Autoinflammatory & rare systemic diseases
Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study
Authors' conclusion
Canakinumab demonstrated superior clinical response and drug survival with fewer adverse events compared with anakinra.
Study context
- Population
- Male patients with VEXAS syndrome treated with IL-1 inhibition, France, Israel and Italy47 patients
- Participants
- 44 vs 9
- Exposure
- Anakinra vs canakinumab
- Anakinran = 44reference
- Canakinumabn = 9
- Outcome
- Global response (GR): absence of inflammatory symptoms and ≥50% decrease in steroid dose and CRP
Methodological detailsinternational
- International
Main finding
As reported in the abstract
GR · 1 month
P < 0.001
Observational data: associations, not effects.
Further findings
GR · 3 months — Anakinra vs Canakinumab
P = 0.001
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| GR · 3 monthsCanakinumabvs AnakinraMultivariable analysis | 28.8 (3.0–273.9) | P = 0.004 | |
| 0.050.21520Odds ratio (log scale) |
| Outcome | Anakinra | Canakinumab | P value |
|---|---|---|---|
| Drug survivalCanakinumab 300 mg/month vs Anakinra · across the three groups | Median 1 (IQR 1–2.5) months | — not stated in the abstract | P = 0.01 |
— not stated in the abstract
- Drug survival: Canakinumab 300 mg/month Median 54 (IQR 30–56) months
- Drug survival: Canakinumab 150 mg/month Median 7 (IQR 4–8) months
Safety
Injection-site reactions
P = 0.006
Infections
P = 0.3
Original publication
Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study. Arthritis Rheumatol. Published 12 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →